v3.26.1
Receivables and Other Assets
 6 Months Ended
Jun. 30, 2026
Trade and other receivables [abstract]  
Receivables and Other Assets
Note 9 - Receivables and Other Assets
June 30,December 31.
20262025
Receivables related to collaboration agreements$969 $907 
Trade receivables related to product sales125 96 
Prepayments81 65 
Interest receivables3 4 
Interest rate swaps10 — 
Other receivables and assets48 62 
Total$1,236 $1,134 
Receivables and other assets - non-current$24 $22 
Receivables and other assets - current1,212 1,112 
Total$1,236 $1,134 

The $102 million increase in receivables and other assets was primarily due to higher DARZALEX and Kesimpta royalties achieved under our collaborations with J&J and Novartis, driven by higher net sales in the second quarter of 2026 as compared to the fourth quarter of 2025, as well as higher trade receivables resulting from increased EPKINLY sales during the same period. Receivables related to DARZALEX and Kesimpta were $886 million at June 30, 2026 compared to $822 million at December 31, 2025, an increase of $64 million or 8%.

Refer to Note 3.6 in the Annual Report for further details regarding Receivables and other assets.